Skip to main content
KNSA logo

Kiniksa Pharmaceuticals International, plc

KNSANASDAQHealthcareDrug Manufacturers - Specialty & Generic

$79.94Today:- (-)1Y +105.40%

As of Oct 15, 2026 close

Market cap
$6.67B
P/E (TTM)
82.66
Forward P/E
39.99
Dividend yield
-
52-week range
$35.20$82.94
Volume (live)
-
Avg. volume (3M)
568.35K

Kiniksa Pharmaceuticals International (KNSA) Financial Ratios

For fiscal 2025 (fiscal year ended Dec 31, 2025), Kiniksa Pharmaceuticals International had a P/E ratio of 52.99, return on equity of 11.7% (up from -9.8%), debt-to-equity of 0.02 (down from 0.02) and a current ratio of 3.79 (up from 3.30). A current ratio of 3.79 means current assets exceed current liabilities.

Kiniksa Pharmaceuticals International Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/E Ratio52.99-87.605.68--
Forward P/E27.3242.92170.84170.84--
P/S Ratio4.613.374.574.7321.04-
P/B Ratio5.513.262.812.634.383.86
Price/Tangible Book5.663.382.932.764.893.86
Price/FCF22.9256.2093.67182.67--
Price/OCF22.6655.5992.75179.37--
Enterprise Value Ratios
EV/Revenue4.112.873.873.8516.02-
EV/EBITDA35.34--69.62--
EV/EBIT36.05--86.73--
EV/FCF20.4147.8179.39148.64--
Profitability & Returns
Return on Equity (ROE)11.73%-9.85%3.37%63.10%-63.55%-60.06%
Return on Assets (ROA)7.18%-5.15%-3.19%1.76%-33.63%-32.57%
Return on Invested Capital (ROIC)27.89%-20.30%-11.05%8.87%-7244.96%-
Return on Capital Employed (ROCE)12.40%-9.50%-5.40%2.40%-83.30%-49.50%
Leverage & Solvency Ratios
Debt/Equity0.020.020.030.010.030.02
Debt/EBITDA0.11--0.38--
Debt/FCF0.070.390.931.04--
Liquidity Ratios
Current Ratio3.793.304.345.164.3810.46
Quick Ratio3.092.843.584.484.1510.16
Efficiency Ratios
Asset Turnover1.010.770.550.640.13-
Inventory Turnover7.566.583.413.72--
Yield & Distribution Ratios
Earnings Yield1.89%-3.02%1.14%17.60%-19.48%-13.42%
FCF Yield4.36%1.78%1.07%0.55%-15.63%-11.37%
Buyback Yield-10.58%0.69%-2.13%-2.69%-10.89%-14.42%

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Kiniksa Pharmaceuticals International Financial Ratios

What is Kiniksa Pharmaceuticals International's P/E ratio?

Kiniksa Pharmaceuticals International's P/E ratio was 52.99 for fiscal 2025 (period ended Dec 31, 2025).

What is Kiniksa Pharmaceuticals International's return on equity?

Kiniksa Pharmaceuticals International's return on equity (ROE) was 11.7% for fiscal 2025 (period ended Dec 31, 2025). It was -9.8% a year earlier.

What is Kiniksa Pharmaceuticals International's debt-to-equity ratio?

Kiniksa Pharmaceuticals International's debt-to-equity ratio was 0.02 for fiscal 2025 (period ended Dec 31, 2025). It was 0.02 a year earlier.

What is return on equity (ROE)?

Return on equity is net income divided by shareholders' equity. It measures how much profit a company generates from the capital its shareholders have invested. Full definition